title: Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia.
abstract: OBJECTIVE
  To describe the clinical features of patients presenting with "idiopathic" interstitial pneumonia that were diagnosed with anti-synthetase syndrome based on clinical features and positive anti-PL-7 or PL-12 antibodies.
  
  
  METHODS
  Over a 24-month period, we evaluated 37 patients who presented with clinical features of anti-synthetase (AS) syndrome, negative anti-Jo-1 antibodies, and who were assessed for other anti-tRNA synthetase (anti-tRS) antibodies. All data were abstracted from the medical record.
  
  
  RESULTS
  Nine (24%) were confirmed to have non-anti-Jo-1 positive AS syndrome based on clinical features and the presence of other anti-tRS antibodies (seven with anti-PL-7, two with anti-PL-12 antibodies). All presented with dyspnea as the initial symptom and with ILD as the first manifestation. Elevated CPK was identified in three patients but only two had muscle weakness. Pulmonary physiology revealed restriction (forced vital capacity 60% of predicted) and impaired gas transfer (diffusing capacity for carbon monoxide 40% of predicted). All had similar findings on thoracic HRCT scans, with basilar predominance of abnormalities and patterns suggestive of non-specific interstitial pneumonia and organizing pneumonia. Immunomodulatory therapies were used to treat the ILD-responses were variable, but some subjects clearly improved.
  
  
  CONCLUSIONS
  Anti-PL-7 and PL-12 antibodies may be more common among patients presenting with "idiopathic" interstitial pneumonia than formerly considered and should be checked in patients with features of AS syndrome despite a negative screen for anti-nuclear or anti-Jo-1 antibodies. Further research is needed to advance understanding of anti-PL-7 or anti-PL-12-positive AS syndrome, including its prognosis and optimal approaches to therapy.
authors.affiliation: National Jewish Health, Interstitial and Autoimmune Lung Disease Program, Denver, CO 80206, United States. fischera@njc.org
authors.forename: Aryeh
authors.initials: A
authors.lastname: Fischer
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Swigris
authors.forename: Roland M
authors.initials: RM
authors.lastname: du Bois
authors.forename: David A
authors.initials: DA
authors.lastname: Lynch
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Downey
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Cosgrove
authors.forename: Stephen K
authors.initials: SK
authors.lastname: Frankel
authors.forename: Evans R
authors.initials: ER
authors.lastname: Fernandez-Perez
authors.forename: JoAnn Z
authors.initials: JZ
authors.lastname: Gillis
authors.forename: Kevin K
authors.initials: KK
authors.lastname: Brown
mesh_terms: D000328:Adult; D000368:Aged; D000412:Alanine-tRNA Ligase / Q000276:immunology; D000604:Amino Acyl-tRNA Synthetases / Q000276:immunology*; D000974:Antibodies, Antinuclear / Q000097:blood*; D003240:Connective Tissue Diseases / Q000175:diagnosis*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D054988:Idiopathic Interstitial Pneumonias / Q000097:blood / Q000276:immunology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013577:Syndrome; D013914:Threonine-tRNA Ligase / Q000276:immunology
chemical_list: D000974:Antibodies, Antinuclear; C046750:Jo-1 antibody; D000604:Amino Acyl-tRNA Synthetases; D013914:Threonine-tRNA Ligase; D000412:Alanine-tRNA Ligase